First mRNA Cancer Vaccine Succeeds in Phase III Trial.

In the phase III INTerpath-0001 trial for resected melanoma, adding the mRNA individualized neoantigen vaccine intismeran autogene to pembrolizumab reduced recurrence or death risk by 42%.

• Why it matters: Recurrence after surgery remains a major challenge in melanoma, and improved adjuvant strategies are needed to extend survival beyond PD-1 blockade alone.
• What they did: The INTerpath-0001 phase III trial tested intismeran autogene given with pembrolizumab after surgery in melanoma patients, assessing time to disease recurrence or death.
• The result: The 42% risk reduction supports the potential of this mRNA neoantigen vaccine strategy to improve outcomes as an adjuvant to PD-1 inhibition.